Glofitamab

Summary

Glofitamab (CHEMBL4298092) is an approved antibody (ATC L01FX28) targeting MS4A1; indicated across 6 conditions including diffuse large b-cell lymphoma and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FX28
• Targets: 1 (MS4A1)
• Indications: 6 conditions
• Clinical trials: 74

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298092
Name	Glofitamab
Type	Antibody
Max phase	4
ATC	L01FX28

Also known as: Columvi, Glofitamab, Glofitamab-gxbm, RG-6026, RG6026, RO-7082859, Ro7082859, RO7082859, GLOFITAMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MS4A1	CD20 (membrane-spanning 4-domains, subfamily A, member 1)	Binding	8.32	0%	P11836

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): MS4A1.

Dominant GO biological processes

GO term	Targets
store-operated calcium entry	1
humoral immune response	1
cell surface receptor signaling pathway	1
response to bacterium	1
B cell differentiation	1
B cell proliferation	1
B cell activation	1
B cell receptor signaling pathway	1
protein tetramerization	1
calcium ion import into cytosol	1
positive regulation of calcium ion import across plasma membrane	1

Indications & clinical

Indications

6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diffuse large B-cell lymphoma	4	MONDO:0018905	EFO:0000403
neoplasm	4	MONDO:0005070	EFO:0000616
lymphoma	3	MONDO:0005062	EFO:0000574
mantle cell lymphoma	2	MONDO:0018876	EFO:1001469
non-Hodgkin lymphoma	1	MONDO:0018908	EFO:0005952
neoplasm of mature B-cells	1	MONDO:0004949	EFO:0000096

Clinical trials

Total trials: 74.

Phase distribution

Phase	Trials
PHASE2	41
PHASE1	13
PHASE1/PHASE2	10
Not specified	5
PHASE3	3
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06956092	PHASE4	NOT_YET_RECRUITING	Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT04408638	PHASE3	ACTIVE_NOT_RECRUITING	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06047080	PHASE3	ACTIVE_NOT_RECRUITING	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06084936	PHASE3	RECRUITING	A Study to Evaluate Glofitamab as a Single Agent vs. Investigator’s Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT03075696	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin’s Lymphoma
NCT03533283	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
NCT04077723	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
NCT04889716	PHASE2	RECRUITING	CAR-T Followed by Bispecific Antibodies
NCT04914741	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
NCT04980222	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
NCT05335018	PHASE2	ACTIVE_NOT_RECRUITING	GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
NCT05533775	PHASE1/PHASE2	RECRUITING	A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
NCT05783596	PHASE2	ACTIVE_NOT_RECRUITING	Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
NCT05798156	PHASE2	ACTIVE_NOT_RECRUITING	Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT05800366	PHASE2	RECRUITING	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
NCT05833763	PHASE2	RECRUITING	A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
NCT05861050	PHASE1/PHASE2	RECRUITING	Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
NCT06043674	PHASE2	RECRUITING	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter’s Transformation
NCT06050694	PHASE2	RECRUITING	Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
NCT06054776	PHASE2	RECRUITING	Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT06071871	PHASE2	RECRUITING	A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
NCT06090539	PHASE1/PHASE2	RECRUITING	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06186648	PHASE2	RECRUITING	Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
NCT06213311	PHASE2	RECRUITING	A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
NCT06252675	PHASE2	RECRUITING	Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
NCT06357676	PHASE1/PHASE2	RECRUITING	Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
NCT06534437	PHASE2	RECRUITING	MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
NCT06552572	PHASE2	ACTIVE_NOT_RECRUITING	Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
NCT06558604	PHASE2	RECRUITING	Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
NCT06567366	PHASE2	NOT_YET_RECRUITING	CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
NCT06570447	PHASE2	RECRUITING	Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
NCT06634589	PHASE1/PHASE2	RECRUITING	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06651853	PHASE2	RECRUITING	Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06656221	PHASE2	NOT_YET_RECRUITING	A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
NCT06765317	PHASE2	RECRUITING	A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
NCT06806033	PHASE2	RECRUITING	A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
NCT06867536	PHASE2	RECRUITING	Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
NCT06996132	PHASE2	RECRUITING	Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
NCT07003295	PHASE2	RECRUITING	Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
NCT07012980	PHASE2	NOT_YET_RECRUITING	Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).